BACKGROUND: Ovarian epithelial carcinomas have recently been classified as slow growing type I tumors and rapidly growing highly aggressive type II tumors. The present study sought to molecularly characterize type I and II tumors using known molecular markers. METHODS: Specimens from 213 patients with ovarian carcinoma were categorized as type I or type II, and evaluated by immunohistochemistry for the inflammatory markers glucose transporter protein-1 (Glut-1), inducible nitric oxide synthase (iNOS), cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and nuclear factor kappa B. Statistical analysis was performed to investigate whether these molecular markers could distinguish between type I and type II tumors. Kaplan-Meier survival curves and COX regression analysis were used to determine the prognostic effect of these markers on survival in the 2 types of tumors. RESULTS: Overexpression of COX-1, COX-2, iNOS, and Glut-1 was significantly higher in type II tumors (P < .05). Women with type II tumors had a poorer median survival (60 months) as compared with those with type I tumors (141 months) (P = .0001). Multivariate analysis revealed type II tumors, late stage, and age >60 years as significant predictors of poor survival. For type II tumors, median survival of patients with tumors overexpressing COX-2 was 44 compared with 85 months for those with tumors with low COX-2 expression (P = .029). Looking at both type I and II tumors, the number of markers simultaneously overexpressed in each tumor was a significant predictor of poor patient survival (P = .005). CONCLUSIONS: The present study demonstrates that the new proposed histologic classification of ovarian epithelial carcinomas correlates with a distinct expression of inflammatory pathway proteins. High expression of these markers may explain the different biologic behavior of these 2 tumor types and provide targets for therapy.
BACKGROUND:Ovarian epithelial carcinomas have recently been classified as slow growing type I tumors and rapidly growing highly aggressive type II tumors. The present study sought to molecularly characterize type I and II tumors using known molecular markers. METHODS: Specimens from 213 patients with ovarian carcinoma were categorized as type I or type II, and evaluated by immunohistochemistry for the inflammatory markers glucose transporter protein-1 (Glut-1), inducible nitric oxide synthase (iNOS), cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), and nuclear factor kappa B. Statistical analysis was performed to investigate whether these molecular markers could distinguish between type I and type II tumors. Kaplan-Meier survival curves and COX regression analysis were used to determine the prognostic effect of these markers on survival in the 2 types of tumors. RESULTS: Overexpression of COX-1, COX-2, iNOS, and Glut-1 was significantly higher in type II tumors (P < .05). Women with type II tumors had a poorer median survival (60 months) as compared with those with type I tumors (141 months) (P = .0001). Multivariate analysis revealed type II tumors, late stage, and age >60 years as significant predictors of poor survival. For type II tumors, median survival of patients with tumors overexpressing COX-2 was 44 compared with 85 months for those with tumors with low COX-2 expression (P = .029). Looking at both type I and II tumors, the number of markers simultaneously overexpressed in each tumor was a significant predictor of poor patient survival (P = .005). CONCLUSIONS: The present study demonstrates that the new proposed histologic classification of ovarian epithelial carcinomas correlates with a distinct expression of inflammatory pathway proteins. High expression of these markers may explain the different biologic behavior of these 2 tumor types and provide targets for therapy.
Authors: Marta Szajnik; Miroslaw J Szczepanski; Esther Elishaev; Carmen Visus; Diana Lenzner; Maciej Zabel; Marta Glura; Albert B DeLeo; Theresa L Whiteside Journal: Gynecol Oncol Date: 2012-08-17 Impact factor: 5.482
Authors: Joanne Kotsopoulos; Kathryn L Terry; Elizabeth M Poole; Bernard Rosner; Megan A Murphy; Jonathan L Hecht; Christopher P Crum; Stacey A Missmer; Daniel W Cramer; Shelley S Tworoger Journal: Int J Cancer Date: 2013-03-13 Impact factor: 7.396
Authors: Amir R Aref; Ruby Yun-Ju Huang; Weimiao Yu; Kian-Ngiap Chua; Wei Sun; Ting-Yuan Tu; Jing Bai; Wen-Jing Sim; Ioannis K Zervantonakis; Jean Paul Thiery; Roger D Kamm Journal: Integr Biol (Camb) Date: 2013-02 Impact factor: 2.192
Authors: Britton Trabert; Elizabeth M Poole; Emily White; Kala Visvanathan; Hans-Olov Adami; Garnet L Anderson; Theodore M Brasky; Louise A Brinton; Renee T Fortner; Mia Gaudet; Patricia Hartge; Judith Hoffman-Bolton; Michael Jones; James V Lacey; Susanna C Larsson; Gerardo G Mackenzie; Leo J Schouten; Dale P Sandler; Katie O'Brien; Alpa V Patel; Ulrike Peters; Anna Prizment; Kim Robien; V Wendy Setiawan; Anthony Swerdlow; Piet A van den Brandt; Elisabete Weiderpass; Lynne R Wilkens; Alicja Wolk; Nicolas Wentzensen; Shelley S Tworoger Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Seema Sethi; Dejuan Kong; Sue Land; Gregory Dyson; Wael A Sakr; Fazlul H Sarkar Journal: Am J Transl Res Date: 2013-03-28 Impact factor: 4.060
Authors: Johan O R Gustafsson; Martin K Oehler; Andrew Ruszkiewicz; Shaun R McColl; Peter Hoffmann Journal: Int J Mol Sci Date: 2011-01-21 Impact factor: 5.923
Authors: Marcela F Paes; Renata D Daltoé; Klesia P Madeira; Lucas Cd Rezende; Gabriela M Sirtoli; Alice L Herlinger; Leticia S Souza; Luciana B Coitinho; Débora Silva; Murilo F Cerri; Ana Cristina N Chiaradia; Alex A Carvalho; Ian V Silva; Leticia Ba Rangel Journal: J Ovarian Res Date: 2011-08-09 Impact factor: 4.234
Authors: Uthpala Seneviratne; Luiz C Godoy; John S Wishnok; Gerald N Wogan; Steven R Tannenbaum Journal: J Am Chem Soc Date: 2013-05-08 Impact factor: 15.419